Processa Pharmaceuticals (PCSA) Company presentation summary
Event summary combining transcript, slides, and related documents.
Company presentation summary
14 Nov, 2026Transaction and capital
Vidya’s equity was exchanged for common stock and newly created Series A non-voting convertible preferred stock in a sign-and-close reverse merger.
A concurrent $200M PIPE is designated for pipeline advancement, working capital and general corporate purposes; pro forma runway is expected into 2029, through multiple clinical milestones.
Expected capitalization after Series A conversion: 2.8M common shares plus 306.6M as-converted preferred shares, totaling 309.4M; subject to stockholder approval and beneficial ownership limits.
VT7208
Potentially best-in-class, once-daily oral BTK inhibitor with preclinical potency, peripheral and CNS target engagement, and consistent efficacy across disease models.
Phase 1 showed favorable safety and tolerability across evaluated doses, with no dose-limiting toxicities, serious adverse events, treatment-related discontinuations, liver safety signal or bleeding-related events.
Median half-life was ~6 hours, supporting once-daily dosing; exposure increased near dose-proportionally and BTK occupancy remained ≥95% for 48 hours after the last dose.
Phase 2 initiation and proof-of-concept data targeted: food allergy H2 2026 and H2 2027; CSU H2 2026 and H1 2028; relapsing MS H1 2027 and H2 2028.
Oral FcRn program
Research collaboration and exclusive option with Generian Pharmaceuticals covers a macrocyclic peptide against the clinically validated FcRn target; work is in lead optimization through development-candidate nomination.
FcRn blockade directs pathogenic IgG, including autoantibodies, to degradation; the mechanism may address IgG-driven diseases including MG, CIDP, ITP and wAIHA.
VYVGART generated $4.15B in 2025 global net sales, up 90% vs. 2024; development-candidate nomination for the oral program is targeted for 2H 2027.
Latest events from Processa Pharmaceuticals
- Vidya expands the pipeline, but acquisition accounting drove a $183.2M Q3 loss.PCSA
Q3 2026 - Vidya deal funds three planned Phase 2 programs into H2 2029, pending key votes.PCSA
Proxy filing - VT-7208’s Phase 2 strategy is funded into 2H 2029, pending key shareholder votes.PCSA
Proxy filing - A reverse split vote is a key step toward Nasdaq listing and a later preferred-conversion vote.PCSA
Proxy filing - Merger and $200 million PIPE set up major conversion dilution and five critical stockholder votes.PCSA
Proxy filing - Reverse split approval is pivotal to Nasdaq listing and preferred-share conversion.PCSA
Proxy filing - A 306.6 million-share resale registration accompanies the shift to VT-7208-led development.PCSA
Registration filing - Merger and $200M PIPE fund VT-7208, a promising BTK inhibitor, into Phase 2 trials.PCSA
Company presentation - Parallel phase II trials for a novel BTK inhibitor are funded through 2029, with key data in 2027–2028.PCSA
H.C. Wainwright 28th Annual Global Investment Conference